0
0
10/4/23 at 3:08pm
Organization
Nature.com
45 words
0
Comments
An orally bioavailable small-molecule active-site inhibitor of the phosphatases PTPN2 and PTPN1, ABBV-CLS-484, demonstrates immunotherapeutic efficacy in mouse models of cancer resistant to PD-1 blockade.
You are the first to view
https://www.nature.com/articles/s41586-023-06575-7
Create an account
or login to join the discussion